A Phase 1, double-blinded, randomized trial of HY02 for treatment of a subset of Anterior ocular surface inflammation

Trial Profile

A Phase 1, double-blinded, randomized trial of HY02 for treatment of a subset of Anterior ocular surface inflammation

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 02 Jun 2017

At a glance

  • Drugs Minocycline (Primary)
  • Indications Ocular inflammation
  • Focus Adverse reactions; First in man
  • Sponsors Hovione
  • Most Recent Events

    • 02 Jun 2017 New trial record
    • 25 May 2017 Hovione expects topline results by the end of 2017, as reported in a media release. Dr. John Sheppard will be Clinical Investigator for this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top